Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 2/20 | 0.34 |
| ▸ | MMP9 | P14780 | 2/20 | 0.34 |
| ▸ | MMP12 | P39900 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1799225 | 0.98 | EPHX1 (0.42) | EPHX1CCNE1CDK2GSK3BMMP1 | |
| SCHEMBL525096 | 0.96 | EPHX1 (0.35) | EPHX1CCNE1CDK2GSK3BMMP1 | |
| SCHEMBL20469204 | 0.92 | CCNE1 (0.38) | CCNE1CDK2GSK3BMGLL | |
| SCHEMBL20629735 | 0.89 | SMN1; SMN2 (0.37) | EPHX1CCNE1CDK2GSK3BSMN1; SMN2 | |
| SCHEMBL1300093 | 0.87 | CCNE1 (0.34) | EPHX1CCNE1CDK2GSK3BMMP1 | |
| SCHEMBL31736019 | 0.87 | CCNE1 (0.34) | EPHX1CCNE1CDK2GSK3BMMP1 | |
| SCHEMBL27365535 | 0.87 | CCNE1 (0.34) | EPHX1CCNE1CDK2GSK3BMMP1 | |
| SCHEMBL1300090 | 0.87 | CCNE1 (0.34) | EPHX1CCNE1CDK2GSK3BMMP1 | |
| SCHEMBL27385617 | 0.87 | CCNE1 (0.34) | EPHX1CCNE1CDK2GSK3BMMP1 | |
| SCHEMBL16746025 | 0.87 | CCNE1 (0.34) | EPHX1CCNE1CDK2GSK3BMMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023149528-A1 | HIGH MOLECULAR MICELLES INCLUDING NOVEL BLOCK COPOLYMER | 株式会社ブレイゾン・セラピューティクス | 2023-08-10 | — | — | WO | disclosed |
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2023-03-30 | — | — | US | disclosed |
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | UNIVERSITY OF MASSACHUSETTS (US) | 2022-10-18 | — | — | US | disclosed |
| US-20200087265-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIV MASSACHUSETTS (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018236928-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | UNIVERSITY OF MASSACHUSETTS (US) | 2018-12-27 | — | — | WO | disclosed |
| US-8927484-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927484-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2422791-B1 | ANTIVIRAL PHOSPHINATE COMPOUNDS | GILEAD SCIENCES INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8809267-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2751090-A1 | ALDH-2 INHIBITORS IN THE TREATMENT OF ADDICTION | Gilead Sciences, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| US-20040229818-A1 | Hepatitis C inhibitor compound | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-11-18 | — | — | US | disclosed |
| EP-1474441-A1 | TRIPEPTIDES HAVING A HYDROXYPROLINE ETHER OF A SUBSTITUTED QUINOLINE FOR THE INHIBITION OF NS3 (HEPATITIS C) | Boehringer Ingelheim International GmbH (DE) | 2004-11-10 | — | — | EP | disclosed |
| EP-1474423-A1 | HETEROCYCLIC TRIPEPTIDES AS HEPATITIS C INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2004-11-10 | — | — | EP | disclosed |
| US-6642204-B2 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-11-04 | — | — | US | disclosed |
| US-20030191067-A1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-10-09 | — | — | US | disclosed |
| US-20030186895-A1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| US-20030187018-A1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-10-02 | — | — | US | disclosed |
| WO-2003064456-A1 | TRIPEPTIDES HAVING A HYDROXYPROLINE ETHER OF A SUBSTITUTED QUINOLINE FOR THE INHIBITION OF NS3 (HEPATITIS C) | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003064456-A1 | TRIPEPTIDES HAVING A HYDROXYPROLINE ETHER OF A SUBSTITUTED QUINOLINE FOR THE INHIBITION OF NS3 (HEPATITIS C) | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003064416-A1 | HETEROCYCLIC TRIPEPTIDES AS HEPATITIS C INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229818-A1 | Hepatitis C inhibitor compound | HAVCR2, GTF3C1, RNASE1 | EPHX1 1187/4885CCNE1 647/4885CDK2 404/4885 |
| US-11472778-B2 | Hepatitis C virus NS3/4A protease inhibitors | HAVCR2, CTSC, DPP4 | EPHX1 931/4885CCNE1 1750/4885CDK2 764/4885 |
| US-20030191067-A1 | Hepatitis C inhibitor tri-peptides | CTRC, CTRL, GTF3C1 | EPHX1 4194/4885CCNE1 1252/4885CDK2 1702/4885 |
| US-20200087265-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | EPHX1 931/4885CCNE1 1750/4885CDK2 764/4885 |
| US-20030186895-A1 | Hepatitis C inhibitor tri-peptides | CTRC, CTRL, GTF3C1 | EPHX1 4194/4885CCNE1 1252/4885CDK2 1702/4885 |
| US-20230099018-A1 | HEPATITIS C VIRUS NS3/4A PROTEASE INHIBITORS | HAVCR2, CTSC, DPP4 | EPHX1 931/4885CCNE1 1750/4885CDK2 764/4885 |
| US-20030187018-A1 | Hepatitis C inhibitor tri-peptides | CTRC, CTRL, NGLY1 | EPHX1 3353/4885CCNE1 977/4885CDK2 2941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.